Literature DB >> 11118382

Differential budding efficiencies of human T-cell leukemia virus type I (HTLV-I) Gag and Gag-Pro polyproteins from insect and mammalian cells.

F Bouamr1, L Garnier, F Rayne, A Verna, N Rebeyrotte, M Cerutti, R Z Mamoun.   

Abstract

In this study, we examined the ability of human T-cell leukemia virus type I (HTLV-I) Gag and Gag-Pro to assemble immature virus-like particles (VLPs) and bud from insect and mammalian cells. Transmission electron microscopy of insect cells infected with a recombinant baculovirus carrying the entire gag gene revealed that Pr53(Gag) is targeted to the plasma membrane, where it extensively accumulates and forms electron-dense evaginations. However, no particles could be detected either inside the cells or in the culture supernatants. With the Gag-Pro-expressing construct, we observed HTLV-I-specific cytoplasmic proteolysis of the Gag precursor, but again no particle released in the culture supernatants. Transmission electron microscopic analysis of insect cells expressing Gag-Pro polyprotein revealed large vacuoles in the cytoplasm and no budding particles at the plasma membrane. In contrast, human immunodeficiency virus type 1 Gag polyprotein expressed in insect cells is able to release VLPs. These data showed that unlike other retroviruses, Pr53(Gag) is unable to be released as immature VLPs from insect cells. To determine whether the block in particle budding and release is due to an intrinsic property of Pr53(Gag) or the absence of essential cellular factors in insect cells, we expressed Gag and Gag-Pro polyproteins in human 293 cells. The results indicate that Pr53(Gag) and p24 capsid are released within particles into the culture supernatants of human 293 cells. We found that the myristylation of the N-terminal glycine residue is essential for Gag release. Altogether, these results strongly suggest that the proper assembly of HTLV-I particles is dependent on mammalian host cell factors. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118382     DOI: 10.1006/viro.2000.0663

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  PR domain of rous sarcoma virus Gag causes an assembly/budding defect in insect cells.

Authors:  M C Johnson; H M Scobie; V M Vogt
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Interrelationship between cytoplasmic retroviral Gag concentration and Gag-membrane association.

Authors:  Keir H Fogarty; Serkan Berk; Iwen F Grigsby; Yan Chen; Louis M Mansky; Joachim D Mueller
Journal:  J Mol Biol       Date:  2013-12-04       Impact factor: 5.469

3.  Analysis of bovine leukemia virus gag membrane targeting and late domain function.

Authors:  Huating Wang; Kendra M Norris; Louis M Mansky
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

4.  Both the PPPY and PTAP motifs are involved in human T-cell leukemia virus type 1 particle release.

Authors:  Huating Wang; Nicholas J Machesky; Louis M Mansky
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

5.  PPPYVEPTAP motif is the late domain of human T-cell leukemia virus type 1 Gag and mediates its functional interaction with cellular proteins Nedd4 and Tsg101 [corrected].

Authors:  Fadila Bouamr; Jessica A Melillo; Margaret Q Wang; Kunio Nagashima; Martha de Los Santos; Alan Rein; Stephen P Goff
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  Alpha interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts.

Authors:  Xuan Feng; Nancy Vander Heyden; Lee Ratner
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 7.  Virus-like particles: models for assembly studies and foreign epitope carriers.

Authors:  Andrzej Palucha; Adrianna Loniewska; Subbian Satheshkumar; Anna M Boguszewska-Chachulska; Mahadevaiah Umashankar; Malgorzata Milner; Anne-Lise Haenni; Handanahal Subbarao Savithri
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2005
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.